Key facts
- This page summarizes Mark C. Schneyer's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
- 7 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 Aug 2026, 18:00.
Mark C. Schneyer - 05 Aug 2026 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)
- Reporting relationship
- EVP, CHIEF FINANCIAL OFFICER
- Issuer ticker
- ACAD
- Reported as of
- 05 Aug 2026
- Net transaction value
- -$587,242
- SEC form
- 4
- Accepted by SEC
- 07 Aug 2026, 18:00:09 UTC
- Prior SEC filing
- 05 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer J. Rhodes, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark C. Schneyer filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 07 Aug 2026.
Change
- Previous filing in this sequence was filed on 05 May 2026.
- Current net transaction value: -$587,242.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001899977
Primary reporting owner
Schneyer Mark C.
- Relationship
- EVP, CHIEF FINANCIAL OFFICER
- Address
- C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO
- Signature
- /s/ Jennifer J. Rhodes, Attorney-in-Fact
- Signature date
- 06 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACAD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +5,849
- Change %
- +8.6%
- Price
- $17.84*
- Shares after
- 73,677
- Date
- 05 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
ACAD
transaction
Common Stock
Sale
- Transaction value
- $169,638
- Shares
- -5,849
- Change %
- -7.9%
- Price
- $29.00
- Shares after
- 67,828
- Date
- 05 Aug 2026
- Ownership
- Direct
- Footnotes
- F2, F3
ACAD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +14,292
- Change %
- +21%
- Price
- $17.84*
- Shares after
- 82,120
- Date
- 06 Aug 2026
- Ownership
- Direct
ACAD
transaction
Common Stock
Sale
- Transaction value
- $145,000
- Shares
- -5,000
- Change %
- -6.1%
- Price
- $29.00
- Shares after
- 77,120
- Date
- 06 Aug 2026
- Ownership
- Direct
- Footnotes
- F2
ACAD
transaction
Common Stock
Sale
- Transaction value
- $272,604
- Shares
- -9,292
- Change %
- -12%
- Price
- $29.34
- Shares after
- 67,828
- Date
- 06 Aug 2026
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACAD
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -5,849
- Change %
- -7.3%
- Price
- $0.000000*
- Shares after
- 74,715
- Date
- 05 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,849
- Exercise price
- $17.84
- Footnotes
- F4
ACAD
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -14,292
- Change %
- -19%
- Price
- $0.000000*
- Shares after
- 60,423
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,292
- Exercise price
- $17.84
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan.
Footnote F2
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F4
25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.